SQ-009 is under clinical development by Seqirus and currently in Phase I for Influenzavirus A Infections. According to GlobalData, Phase I drugs for Influenzavirus A Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SQ-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SQ-009 overview

SQ-009 is under development for the prevention of infection caused by pandemic influenza virus strain A/H2N3, in age-group 18 years and above. It is a cell culture derived, MF59 adjuvanted H2N3 vaccine (aH2N3c A/Chicken/Ohio/494832/2007). It is administered through intramuscular route.

Seqirus overview

Seqirus, a subsidiary of CSL Ltd, is a pharmaceutical company that manufactures and markets influenza, antivenoms, and pharmaceutical products. The company is headquartered in Maidenhead, Berkshire, the UK.

For a complete picture of SQ-009’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.